Emily Rayner (F) is a scientist in preclinical ex vivo model development in the Department of Human Cell Biology at TNO in Leiden, The Netherlands. She obtained her PhD in Clinical Medicine from the University of Oxford and subsequently held a postdoctoral position at Leiden University Medical Center. Her academic research focused on mechanisms by which diet‑derived chemicals influence mutagenesis and gastrointestinal cancer development. At TNO, her work is centred on the development and application of human‑relevant preclinical ADME models of the intestine, liver, kidney and vagina. She has particular expertise in ex vivo tissue and organ perfusion platforms to support translational assessment of pharmaceutical and nutritional compounds. She (co)authored more than 11 publications with an h-index of 9.